AIM: : The purpose of the present study was to compare clinically the treatment of deep intrabony defects with a combination of a bovine-derived xenograft (BDX) and a bioresorbable collagen membrane to access flap surgery. METHODS: : Twenty-eight patients suffering from chronic periodontitis, and each of whom displayed one intrabony defect, were randomly treated with BDX + collagen membrane (test) or with access flap surgery (control). Soft tissue measurements were made at baseline and at 1 year following therapy. RESULTS: : No differences in any of the investigated parameters were observed at baseline between the two groups. Healing was uneventful in all patients. At 1 year after therapy, the test group showed a reduction in mean probing depth (PD) from 9.2+/-1.3 to 3.9+/-0.7 mm (p<0.001) and a change in mean clinical attachment level (CAL) from 10.2+/-1.5 to 6.2+/-0.5 mm (p<0.0001). In the control group, the mean PD was reduced from 9.0+/-1.2 to 5.2+/-1.8 mm (p<0.001) and the mean CAL changed from 10.5+/-1.5 to 8.4+/-2.1 mm (p<0.01). The test treatment resulted in statistically higher PD reductions (p<or=0.05) and CAL gains (p<0.001) than the control one. In the test group all sites (100%) gained at least 3 mm of CAL. In the control group no CAL gain occurred in four sites (29%), whereas at six sites (43%) the CAL gain was 2 mm. A CAL gain of 3 mm or more was measured in four defects (29%). CONCLUSIONS: : Within the limits of the present study, it can be concluded that: (i) at 1 year after surgery both therapies resulted in significant PD reductions and CAL gains, and (ii) treatment with BDX+collagen membrane resulted in significantly higher CAL gains than treatment with access flap surgery.
RCT Entities:
AIM: : The purpose of the present study was to compare clinically the treatment of deep intrabony defects with a combination of a bovine-derived xenograft (BDX) and a bioresorbable collagen membrane to access flap surgery. METHODS: : Twenty-eight patients suffering from chronic periodontitis, and each of whom displayed one intrabony defect, were randomly treated with BDX + collagen membrane (test) or with access flap surgery (control). Soft tissue measurements were made at baseline and at 1 year following therapy. RESULTS: : No differences in any of the investigated parameters were observed at baseline between the two groups. Healing was uneventful in all patients. At 1 year after therapy, the test group showed a reduction in mean probing depth (PD) from 9.2+/-1.3 to 3.9+/-0.7 mm (p<0.001) and a change in mean clinical attachment level (CAL) from 10.2+/-1.5 to 6.2+/-0.5 mm (p<0.0001). In the control group, the mean PD was reduced from 9.0+/-1.2 to 5.2+/-1.8 mm (p<0.001) and the mean CAL changed from 10.5+/-1.5 to 8.4+/-2.1 mm (p<0.01). The test treatment resulted in statistically higher PD reductions (p<or=0.05) and CAL gains (p<0.001) than the control one. In the test group all sites (100%) gained at least 3 mm of CAL. In the control group no CAL gain occurred in four sites (29%), whereas at six sites (43%) the CAL gain was 2 mm. A CAL gain of 3 mm or more was measured in four defects (29%). CONCLUSIONS: : Within the limits of the present study, it can be concluded that: (i) at 1 year after surgery both therapies resulted in significant PD reductions and CAL gains, and (ii) treatment with BDX+collagen membrane resulted in significantly higher CAL gains than treatment with access flap surgery.
Authors: Péter Windisch; Andreas Stavropoulos; Bálint Molnár; Dóra Szendröi-Kiss; Emese Szilágyi; Péter Rosta; Attila Horváth; Björn Capsius; Ulf M E Wikesjö; Anton Sculean Journal: Clin Oral Investig Date: 2011-09-02 Impact factor: 3.573